Ministry of Health Flags Off Critical Human Immunodeficiency Virus (HIV) Commodities at Mission for Essential Drugs and Supplies (MEDS) ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Merck (MRK) announced the presentation of “positive” results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug ...

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

Cheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people becoming infected, could be available in the UK following a court ruling.

Tenofovir disoproxil fumarate (TDF ... half-life of approximately 150 hours versus 39 hours for FTC. Both drugs are concentrated in genital secretions as compared to plasma which is desirable ...

The EMA validation follows the announcement last week that the U.S. Food and Drug and Administration ... when compared with once-daily oral Truvada® (emtricitabine 200mg and tenofovir disoproxil ...

The authors call for close monitoring of renal function and serum electrolyte and cation levels in patients beginning tenofovir with any of these drugs, in the hopes that early diagnosis of ...

(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA ... of HIV infections when compared with once-daily oral Truvada® (emtricitabine 200mg and tenofovir disoproxil ...